Crystalline solid forms and the amorphous form of the anti-HCV compound 5-(3,3-dimethylbutyn-1-yl)-3-[(cis-4-hydroxy-4-[(3S)-tetrahydrofuran-3-yloxy]methyl}cyclohexyl)[(1R)-4-methylcyclohex-3-en-1-yl]carbon yl}amino]thiophene-2-carboxylic acid (Compound I) were prepared and characterized in the solid state. Also provided are processes of manufacture and methods of using the crystalline forms.
晶体固态形式和抗HCV化合物5-(
3,3-二甲基丁炔-1-基)-3-[(顺式-
4-羟基-4-[(3S)-
四氢呋喃-3-氧基]甲基}环己基)[(1R)-4-甲基环己-3-烯-1-基]羰基}
氨基]
噻吩-2-
羧酸(化合物I)的非晶形式已在固态中制备和表征。还提供了制备晶体形式的方法和使用方法。